AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-21

New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(0) · ALS(0) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
No new qualifying paper for this issue.
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Parkinson’s disease (PD) progresses heterogeneously, yet no reliable biomarker stratifies patients for individualized care. We developed DEGAS, a machine learning framework applying functional connectivity to identify network-defined PD subtypes. Baseline functional MRI from 336 early-stage patients was stratified by suspected REM sleep behavior disorder (sRBD), a marker of aggressive disease. Adjacency matrices and graph theory metrics were integrated into classifiers, and predictions validated against three-year outcomes. Region-of-interest analyses showed no group differences in connectivity or topology. By contrast, models incorporating graph theory features achieved robust classification (balanced accuracy 0.91–0.93; MCC 0.61–0.78), outperforming adjacency-only models (balanced accuracy 0.79; MCC 0.52). Metrics that represented the basal ganglia-thalamic, temporal-limbic, and cerebello-cortical circuits were the strongest predictors. Patients classified as sRBD-positive showed worse motor outcomes, accelerated autonomic dysfunction, and higher rates of hallucinations, dyskinesias, and depression. The DEGAS framework defines a baseline network signature marking clinically distinct PD subgroups. External validation is required before clinical use is considered.
Journal IF-equivalent: 8.0 (OpenAlex 2-year mean citedness, value as of 2026-10-20, retrieved 2026-10-21; not the official Clarivate IF)Reference: Martinez-Nunez AE, Pontone GM, Barmpoutis A, Okun MS, Vaillancourt DE, Wong JK. DEGAS, disease endophenotyping through graph and adjacency metrics: network biomarkers for Parkinson’s disease progression. npj Parkinsons Dis. 2026 Nov 18 [Epub ahead of print]. doi:10.1038/s41531-026-01602-6.Checked: Abstract only - Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, yet reliable and minimally invasive biomarkers for accurate diagnosis and clinical stratification remain lacking. Here, we aimed to identify plasma-based protein biomarkers with diagnostic and differential utility for PD. Plasma samples from 391 participants were analyzed using a two-stage design. In the discovery phase, label-free quantitative proteomics identified differentially expressed proteins between patients with PD and healthy controls, followed by functional enrichment analyses. A machine learning–based feature selection strategy was used to derive candidate biomarker panels. In the validation phase, selected proteins were quantified by enzyme-linked immunosorbent assay in an independent cohort including patients with PD, patients with multiple system atrophy, Parkinsonian type (MSA-P), and healthy controls. Diagnostic performance was evaluated using receiver operating characteristic analyses, and associations with clinical features were examined. Proteomic profiling identified 121 differentially expressed proteins related to vesicle trafficking, oxidative stress, and autophagy. A plasma protein panel comprising LAMP1, APOD, VIM, CTSF, and HEG1 showed robust performance in distinguishing PD from healthy controls, while a simplified combination moderately differentiated PD from MSA-P. Selected biomarkers were also associated with clinical scales of cognition and non-motor symptoms, supporting the potential utility in the clinical assessment of PD.
Journal IF-equivalent: 8.0 (OpenAlex 2-year mean citedness, value as of 2026-10-20, retrieved 2026-10-21; not the official Clarivate IF)Reference: Liu R, Kong Y, Fan L, Li L, yuan J, Zhang K, et al. Machine learning-based plasma proteomics discovers biomarkers for the early diagnosis of Parkinson’s disease. npj Parkinsons Dis. 2026 Nov 17 [Epub ahead of print]. doi:10.1038/s41531-026-01606-2.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
- Abstract
Background/Objectives: Artificial intelligence (AI) tools are becoming increasingly utilised in everyday radiological practice. Evaluating follow-up magnetic resonance imaging (MRI) of patients with multiple sclerosis (MS) is challenging. The aim of this study was to assess changes in confidence among four participating radiology residents when evaluating follow-up MRIs of MS patients using Pixyl.Neuro.MS® software.
Methods: This retrospective study included 78 MS patients. Previous and new FLAIR images were independently analysed by four residents, first without AI and then in an immediate AI-assisted second reading using Pixyl.Neuro.MS®, a deep-learning lesion-segmentation software. Readers recorded their findings and confidence after each reading and rated the impact and usefulness of AI. The reference standard was defined by a consensus reading of a neuroradiologist and a radiology resident (15 and 4 years of experience). Paired analyses and patient-level bootstrap confidence intervals were used; bootstrap inference was conditional on the four readers.
Results: The reference standard identified 24 patients with new lesions. Mean accuracy across readers increased from 84.62% to 90.71% (difference, 6.09 percentage points; 95% bootstrap confidence interval [CI], 2.24–10.26). Only Reader 3 showed a significant accuracy increase after Holm adjustment (p = 0.025). No accuracy comparison with routine reports was significant after adjustment. Confidence increased for all readers (all Holm-adjusted p < 0.001). Perceived usefulness did not differ significantly between lesion-burden groups. All readers predominantly rated the impact of AI as positive. The second-reading phase was shorter by a mean of 59.35 s (95% bootstrap CI, 51.39–67.07).
Conclusions: In these four residents, the AI-assisted second reading was associated with higher confidence and average accuracy. The immediate sequential design prevents separation of AI contributions from familiarity and order effects, and the shorter second-reading phase does not establish an overall workflow time saving.
Journal IF-equivalent: 5.9 (OpenAlex 2-year mean citedness, value as of 2026-11-19, retrieved 2026-11-20; not the official Clarivate IF)Reference: Mastilovic M, Tomlinson A, Traore WYM, Alkatheeri M, Romčević I, Boban J, et al. AI-Assisted Follow-Up MRI Interpretation in Multiple Sclerosis: Radiology Residents’ Diagnostic Confidence and Performance. Diagnostics. 2026 Nov 18;16(22):3866. doi:10.3390/diagnostics16223866.Checked: Abstract only
See all 1 Multiple sclerosis papers →
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.